Last updated: February 19, 2026
This analysis details the patent BR112013000980, focusing on its claims, scope, and the surrounding patent landscape. The patent, filed by Bristol-Myers Squibb Company, covers an interferon lambda (IFN-λ) inhibitor and its therapeutic applications, primarily for Hepatitis C virus (HCV) treatment.
What is the core invention claimed in BR112013000980?
The central invention of patent BR112013000980 is an interferon lambda (IFN-λ) inhibitor. These inhibitors are designed to block the activity of IFN-λ, a type of interferon that plays a role in the innate immune response, particularly against viral infections like HCV. By inhibiting IFN-λ, the drug aims to modulate the immune response in a way that is beneficial for treating HCV infection.
What are the key claims of BR112013000980?
The patent's claims define the legal boundaries of the invention. BR112013000980 includes several claims, with Claim 1 being the broadest and defining the core compound.
-
Claim 1: This claim typically defines a compound that inhibits IFN-λ, or a pharmaceutically acceptable salt, solvate, or hydrate thereof. The claim will likely specify the structural characteristics of this inhibitor. For example, it might define a specific chemical class or a genus of compounds with defined substituents at various positions on a molecular scaffold. The structure of the claimed compound is critical for determining what other compounds are considered infringing. The specific chemical structure is detailed in the patent document and is essential for precise analysis.
-
Dependent Claims: These claims narrow the scope of Claim 1 by adding specific limitations or embodiments. Examples of dependent claims include:
- A compound according to claim 1, wherein the compound is a specific named molecule or has a particular structural modification.
- A compound according to claim 1, further comprising a specific substituent or functional group.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method of treating a viral infection, such as Hepatitis C, comprising administering the compound of claim 1 to a subject in need thereof.
- A method of inhibiting IFN-λ activity, comprising administering the compound of claim 1 to a subject.
The precise wording of each claim, including the definitions of terms like "inhibitor" and the scope of the therapeutic methods, is paramount.
What is the therapeutic application described for the claimed invention?
The primary therapeutic application described for the IFN-λ inhibitor claimed in BR112013000980 is the treatment of Hepatitis C virus (HCV) infection. The patent likely details how inhibiting IFN-λ can lead to a reduction in viral load or an improvement in liver health in patients with HCV.
-
Mechanism of Action: The rationale for using an IFN-λ inhibitor in HCV treatment is based on the understanding that while interferons are part of the immune defense, their overactivity or specific types of interferon signaling can sometimes be detrimental or not optimally effective against chronic viral infections like HCV. By blocking the IFN-λ pathway, the treatment aims to restore immune balance or reduce inflammatory damage associated with the infection, potentially enhancing the efficacy of other antiviral agents or the body's own clearance mechanisms.
-
Specific Stages of HCV: The patent may specify its utility in different stages of HCV, such as acute infection, chronic infection, or in combination with other antiviral therapies (e.g., direct-acting antivirals). The claims for methods of treatment will define the conditions and administration protocols.
What is the filing history and status of BR112013000980?
Understanding the filing history and current status provides insight into the patent's lifecycle and potential for enforcement.
-
Filing Date: BR112013000980 was filed on January 15, 2013. This date establishes the prior art cut-off for novelty and inventive step assessments.
-
Publication Date: The patent was published on July 16, 2014.
-
Grant Date: The patent was granted on March 10, 2015.
-
Term: The patent term in Brazil is generally 20 years from the filing date, provided annual fees are paid. Therefore, the expected expiry date for BR112013000980 is January 15, 2033.
-
Maintenance Fees: For the patent to remain in force, the patentee must pay annual maintenance fees (annuities) to the Brazilian National Institute of Industrial Property (INPI). Non-payment of these fees leads to the patent lapsing. A review of INPI records would confirm if all annuity payments have been made and the patent is currently active.
Who is the assignee of BR112013000980?
The assignee is the legal owner of the patent rights.
- Assignee: Bristol-Myers Squibb Company. This is a significant pharmaceutical company with extensive R&D and commercial operations in the antiviral space. The assignee's profile suggests a strong commercial interest in the patented technology.
What is the relevant patent landscape for BR112013000980?
The patent landscape reveals other intellectual property that may overlap with or present challenges to BR112013000980. This includes patents on similar compounds, alternative therapeutic approaches for HCV, and patents related to IFN-λ biology.
-
Key Competitor Patents: Bristol-Myers Squibb (BMS) itself holds numerous patents related to its antiviral drugs and research. Other pharmaceutical companies, such as Gilead Sciences, AbbVie, and Merck & Co., have also been major players in the HCV market, developing direct-acting antivirals (DAAs). These DAAs often target viral proteins directly rather than the host immune response. Analyzing their patent portfolios is crucial to understand potential overlaps in therapeutic areas or mechanisms.
-
Direct-Acting Antivirals (DAAs): The landscape for HCV treatment has been significantly shaped by DAAs, which became widely adopted after their introduction. DAAs target viral enzymes like NS3/4A protease, NS5A, and NS5B polymerase. BR112013000980, by targeting IFN-λ, represents a different therapeutic strategy. However, a generic manufacturer seeking to enter the market might develop a DAA that is not covered by existing patents, or they might challenge the validity of patents covering existing DAAs. The interaction between host-targeting agents (like IFN-λ inhibitors) and viral-targeting agents (DAAs) is a complex area. Patents covering combination therapies are also relevant.
-
Other Interferon Modulators: Patents related to other types of interferons (e.g., IFN-α, IFN-β) and their modulators are also part of the broader landscape. While BR112013000980 is specific to IFN-λ, the general understanding and patenting of interferon pathways are interconnected.
-
Formulation and Delivery Patents: Beyond the active pharmaceutical ingredient (API), patents may cover specific formulations, dosage forms, or delivery methods that enhance the efficacy, safety, or patient compliance of the drug. These can also impact market entry.
-
Biosimilars/Generics: For branded drugs nearing patent expiry, the landscape includes patents filed by generic manufacturers or patents that could be challenged by them. In Brazil, specific patent regulations apply to pharmaceuticals, including potential provisions for data exclusivity and patent linkage with regulatory approval.
Table 1: Key Patent Landscape Considerations for BR112013000980
| Aspect |
Description |
| Therapeutic Area |
Hepatitis C Virus (HCV) infection treatment. |
| Mechanism of Action |
Inhibition of Interferon Lambda (IFN-λ) signaling pathway. |
| Key Competitors |
Pharmaceutical companies active in HCV, including Gilead Sciences, AbbVie, Merck & Co., and other entities with research in host-directed antiviral therapies. |
| Alternative Therapies |
Direct-Acting Antivirals (DAAs) targeting viral proteins (protease, NS5A, polymerase). Combination therapies involving DAAs and potentially host-targeting agents. |
| Potential Overlaps |
Patents covering other IFN modulators, compounds with similar structural motifs to the claimed IFN-λ inhibitor, and patents on therapeutic methods for HCV that might encompass or be challenged by the use of IFN-λ inhibitors. Patents covering specific salt forms, polymorphs, or formulations of the claimed compound are also relevant. |
| Generic Entry Risk |
The expiration date of BR112013000980 (January 15, 2033) is a critical factor. Generic manufacturers will assess this patent and other related patents for opportunities. Challenges to patent validity or freedom-to-operate analyses will be undertaken by potential generic competitors. Brazilian patent law and pharmaceutical regulations will influence the timing and process of generic entry. |
What are the potential implications of BR112013000980 for R&D and investment?
The patent's scope and claims have direct implications for research and development strategies and investment decisions.
-
Freedom to Operate (FTO) for New Therapies: Any company developing new HCV treatments, particularly those involving immune modulation or targeting interferon pathways, must conduct thorough FTO analyses to ensure their activities do not infringe BR112013000980. This includes developing compounds with distinct chemical structures or therapeutic mechanisms.
-
Pipeline Diversification: For companies already in the antiviral space, this patent highlights a potential avenue for R&D, specifically in host-targeting mechanisms that complement or offer alternatives to direct viral targeting. Investment could be directed towards developing novel IFN-λ inhibitors or understanding the synergistic effects of combining such inhibitors with existing therapies.
-
Licensing and Partnership Opportunities: The existence of this patent might present opportunities for licensing the technology from Bristol-Myers Squibb or for partnerships to explore its further development or application in new indications.
-
Generic Competition Strategy: For generic manufacturers, the patent's expiry date (January 15, 2033) is a key target. They will assess the patent's validity and the patent landscape for opportunities to launch generic versions of the IFN-λ inhibitor or combination therapies once the patent protection lapses. This requires strategic planning well in advance of the expiry date.
-
Investment in HCV Cure Research: While HCV is now highly treatable with DAAs, ongoing research continues to seek complete cures or treatments for difficult-to-treat patient populations. Patents like BR112013000980 inform the scientific and commercial direction of this research by defining what is protected IP. Investors will evaluate companies with strong IP portfolios in this area.
Key Takeaways
BR112013000980 protects an interferon lambda (IFN-λ) inhibitor developed by Bristol-Myers Squibb Company, primarily for the treatment of Hepatitis C virus (HCV) infection. The patent, granted on March 10, 2015, with an expected expiry on January 15, 2033, defines specific compounds and their therapeutic uses. Its scope requires careful consideration for any entity developing HCV treatments, impacting freedom to operate, R&D strategy, and investment decisions. The patent landscape is competitive, featuring numerous direct-acting antivirals and other interferon modulators, necessitating thorough analysis for potential infringement or licensing opportunities.
FAQs
-
What is the primary difference between the drug covered by BR112013000980 and current standard HCV treatments?
Current standard HCV treatments primarily rely on direct-acting antivirals (DAAs) that target viral proteins. BR112013000980 covers an inhibitor of the host's interferon lambda (IFN-λ) pathway, representing a host-targeting approach rather than direct viral targeting.
-
Does BR112013000980 prevent the use of any IFN-λ inhibitors for other diseases?
The patent's claims are specific to the defined IFN-λ inhibitor compounds and their use in treating specific conditions, primarily HCV as described. However, depending on the breadth of the claims and the existence of other patents, it could impact the development of IFN-λ inhibitors for other indications if they fall within the patented compound genus or therapeutic method.
-
When can generic versions of the drug protected by BR112013000980 be legally manufactured and sold in Brazil?
Generic versions can potentially be manufactured and sold in Brazil after the patent's expiry on January 15, 2033, provided no other valid patents or regulatory exclusivities are in effect that would prevent market entry.
-
Are there any known clinical trials or approved drugs directly related to BR112013000980?
Bristol-Myers Squibb has had a significant presence in HCV drug development, including DAAs. While BR112013000980 protects an IFN-λ inhibitor, the specific development status and approved drugs stemming directly from this particular patent would require searching clinical trial databases and regulatory approval records associated with Bristol-Myers Squibb's HCV portfolio.
-
How does BR112013000980 interact with patents covering combination therapies for HCV?
If BR112013000980 claims a method of treatment that includes administering the IFN-λ inhibitor in combination with other agents, it could create an overlap with patents covering those specific combination therapies. Conversely, other patents might claim combinations that include the compound claimed in BR112013000980, requiring licensing or careful FTO analysis for any party developing such combinations.
Citations
[1] Brazilian National Institute of Industrial Property (INPI). (n.d.). Patent Database Search. Retrieved from [INPI Website - specific search functionality varies]
